RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
PACAP stands for pituitary adenylate cyclase-activating polypeptide. It is studied as a signaling molecule, including in research on blood vessels and migraine. The direction of an intervention is crucial: experimental PACAP exposure has triggered migraine-like attacks, while a separate clinical program has investigated an antibody that blocks PACAP. Evidence for blocking a signal cannot be used to claim benefits from adding that signal. This overview follows three original studies from the discovery of PACAP38 to human migraine experiments and an antibody trial. [1–3]
WHAT DID THE DISCOVERY STUDY SHOW?
In 1989, Miyata and colleagues isolated a 38-amino-acid peptide from sheep hypothalamic tissue and examined its activity in rat pituitary-cell cultures. The peptide strongly stimulated adenylate cyclase, an enzyme involved in producing the intracellular signaling molecule cyclic AMP. The researchers also observed hormone-release responses in their experimental cell system. [1]
This work established a biochemical basis for studying PACAP38. It did not demonstrate that administering PACAP improves health in humans. The species, tissue preparation and measured response define the result. A strong effect in a cellular assay is not a general measure of clinical usefulness or safety.
PACAP38 IN A HUMAN MIGRAINE MODEL
Schytz and colleagues conducted separate randomized, double-blind crossover experiments in twelve healthy volunteers and twelve people with migraine without aura. PACAP38 caused headache in all healthy participants and eleven of the twelve participants with migraine. Seven participants in the migraine group developed migraine-like attacks after PACAP38, compared with none after placebo. Many attacks were delayed until after the initial observation period. [2]
The investigators also measured vascular changes. Together, the findings supported a role for PACAP-related signaling in migraine research. They do not support describing native PACAP as a migraine-relief compound. This was a provocation model, meaning the experiment deliberately examined whether a biological signal could produce symptoms under controlled conditions.
AN ANTIBODY TRIAL TESTED THE OPPOSITE DIRECTION
A phase 2 trial reported by Ashina and colleagues in 2024 enrolled 237 adults with migraine whose previous preventive treatments had been unsuccessful. The investigational antibody Lu AG09222 was designed to target PACAP itself. Participants were assigned to two antibody groups or placebo. In the main comparison, monthly migraine days decreased by 6.2 days in the higher antibody group and 4.2 days with placebo during weeks one through four, a between-group difference of two days. [3]
The primary result favored the antibody, but the study was relatively short and evaluated an investigational pharmaceutical product. Adverse events reported more frequently in the main antibody group included fatigue, nasopharyngitis and COVID-19. The trial was funded by the antibody's developer. Longer and broader studies are needed to characterize durability and safety. [3]
WHY PACAP AND AN ANTI-PACAP ANTIBODY ARE NOT INTERCHANGEABLE
PACAP is the signaling peptide. An anti-PACAP antibody is a different molecule designed to reduce that signal's activity. A positive antibody result is therefore evidence about blocking the pathway in a defined setting. It cannot be transferred to a research vial containing PACAP, and it does not establish that a separately sourced material matches either clinical study product.
The same distinction applies when reading other mechanistic research. A pathway may have different effects across tissues and conditions. A favorable cellular observation cannot cancel a human symptom-provoking result, nor does one negative effect describe every possible biological role.
WHAT THE SELECTED EVIDENCE SUPPORTS
These publications establish PACAP as a scientifically important signaling molecule and support investigation of its role in migraine. They also demonstrate why the test material and direction of intervention must stay attached to every claim. Native-peptide experiments, pathway-blocking trials and laboratory research products represent different evidence questions. None of the studies reviewed here validates personal use of a PACAP research material.
REFERENCES
1. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochemical and Biophysical Research Communications. 1989;164:567–574.
https://doi.org/10.1016/0006-291X(89)91757-9
2. Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132:16–25.
https://doi.org/10.1093/brain/awn307
3. Ashina M, Phul R, Khodaie M, Löf E, Florea I. A Monoclonal Antibody to PACAP for Migraine Prevention. New England Journal of Medicine. 2024;391:800–809.
https://doi.org/10.1056/NEJMoa2314577